• 1. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 2. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

The Compound CAS No. 1208076-55-4: (1-Ethyl-3-methyl-1H-pyrazol-4-yl)methanamine Hydrochloride

(1-Ethyl-3-methyl-1H-pyrazol-4-yl)methanamine hydrochloride, identified by the CAS number 1208076-55-4, is a compound of significant interest in the fields of organic chemistry and pharmacology. This compound belongs to the class of pyrazole derivatives, which have been extensively studied for their diverse biological activities and potential applications in drug discovery.

The structure of this compound consists of a pyrazole ring substituted with an ethyl group at position 1, a methyl group at position 3, and a methanamine group at position 4, which is further protonated as a hydrochloride salt. The pyrazole ring is a five-membered aromatic heterocycle containing two nitrogen atoms, making it a versatile scaffold for various chemical modifications and biological interactions.

Recent studies have highlighted the potential of pyrazole derivatives as inhibitors of various enzymes and receptors, making them promising candidates for the development of new therapeutic agents. For instance, research has shown that certain pyrazole-containing compounds exhibit potent anti-inflammatory, antioxidant, and anticancer activities. These findings underscore the importance of understanding the structure-property relationships in such compounds to optimize their therapeutic potential.

In terms of synthesis, the preparation of (1-Ethyl-3-methyl-1H-pyrazol-4-yl)methanamine hydrochloride involves a multi-step process that typically includes the formation of the pyrazole ring followed by substitution reactions to introduce the desired substituents. The hydrochloride salt form is often preferred for its enhanced solubility and stability, which are critical factors in drug delivery systems.

One of the most recent advancements in this area involves the use of computational chemistry techniques to predict the bioavailability and pharmacokinetic properties of pyrazole derivatives. These computational models have provided valuable insights into how structural modifications can influence the compound's absorption, distribution, metabolism, and excretion (ADME) profiles.

Moreover, in vitro studies have demonstrated that this compound exhibits selective binding to certain protein targets, suggesting its potential as a lead compound for drug development. Collaborative efforts between academic institutions and pharmaceutical companies have further accelerated research into optimizing its efficacy and reducing potential side effects.

In conclusion, (1-Ethyl-3-methyl-1H-pyrazol-4-yl)methanamine hydrochloride (CAS No. 1208076-55-) represents a compelling example of how structural diversity in heterocyclic compounds can lead to innovative therapeutic solutions. As research continues to uncover its full potential, this compound stands at the forefront of advancements in medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)